Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA).

MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism.

Key Publication Highlights:

Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more

Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.